Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET

Company Participants

Justine Koenigsberg - VP, IR
Nello Mainolfi - Founder, President & CEO
Jared Gollob - Chief Medical Officer
Bruce Jacobs - CFO

Conference Call Participants

Marc Frahm - TD Cowen
Kalpit Patel - B. Riley
Alexei Siniakov - Truist Securities
Brad Canino - Stifel Nicolaus
Gospel Enyindah-Asonye - Morgan Stanley
Kelly Shi - Jefferies
Jeff Jones - Oppenheimer
Eric Joseph - J.P. Morgan
Michael Schmidt - Guggenheim Securities
Faisal Khurshid - Leerink Partners

Operator

Good day, and welcome to the Kymera Therapeutics Third Quarter 2024 Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After the today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would like now to turn the conference over to Justine Koenigsberg, Head of Investor Relations. Please go ahead.

Justine Koenigsberg

Thank you. Good morning, and welcome to Kymera's quarterly update call. Joining me this morning are Nello Mainolfi, Founder, President and CEO; Jared Gollob, our Chief Medical Officer; and Bruce Jacobs, our Chief Financial Officer. Please note that during Jared's remarks, we intend to reference data from slides in our corporate presentation, which is available within the IR section of our website at kymeratx.com. Following our prepared remarks, we will open the call to questions. We ask that you please limit your questions to one and a relevant follow-up to assure we have enough time to address everyone's questions.

Before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call.

With that, I will now turn the call over to Nello.

Nello Mainolfi

Thank you, Justine, and good morning, everybody. We have a lot of important updates today, so let's jump right in. First and foremost, we're extremely excited that we have started the Phase 1 study of KT-621, our first-in-class oral STAT6 degrader and the first STAT6 medicine to ever enter clinical development. It's important to highlight that we were able to accelerate the path to the clinic given our recent increased focus of resources and capital that we're directing towards our growing immunology pipeline. I believe this is also an important moment for the whole industry.